Research And Growth > Grants

Research Grants in Prematurity & Preeclampsia

2018 research grants are now available to researchers interested in improving the health of mothers and neonates.

AMAG Pharmaceuticals, Inc. is committed to funding research aimed at reducing the risk of premature birth and preeclampsia in order to improve the health of neonates and infants in the United States through its Prematurity and Preeclampsia Research Grants Program.

 

AMAG Pharmaceuticals awarded more than $300,000 in research grants in 2017 to the following principal investigators to support the important research they are conducting focused on prematurity prevention:

 

  • Akila Subramaniam, MD, MPH, an Associate Professor at the University of Alabama at Birmingham, Department of Obstetrics and Gynecology, who is researching the relationship of the cervico-vaginal microbiome to local inflammation, cervical length shortening and ultrasound-indicated cerclage success;
  • Cynthia Gyamfi-Bannerman, MD, MSc, the Ellen Jacobson Levine and Eugene Jacobson Associate Professor of Obstetrics and Gynecology and Co-Director of the Preterm Birth Prevention Center, and Whitney A. Booker, MD, Maternal-Fetal Medicine Fellow at New York-Presbyterian/Columbia University Medical Center, who are researching quantitative activity levels and the possible relationship to gestational age at delivery among nulliparous women;
  • Jacqueline Parchem, MD, an Assistant Professor at the McGovern Medical School, University of Texas Health Science Center at Houston in the Department of Obstetrics, Gynecology & Reproductive Sciences who is researching the role of amniotic fluid exosomes in fetal development and placental membrane health; and
  • Kaylon Bruner-Tran, PhD, an Associate Professor in the Department of Obstetrics and Gynecology at Vanderbilt University School of Medical and co-director of the Women’s Reproductive Health Research Center at Vanderbilt University Medical Center, who is examining mechanisms to eliminate the paternal-derived risks of preterm birth.

 

The company is pleased to announce that it will be funding research grants in prematurity and preeclampsia in 2018 for a total of $300,000. Consideration will be given to basic or clinical research in maternal, fetal and neonatal/infant health. All proposals will be evaluated and the final awards will be determined based on scientific merit by an external review panel comprised of experts in the field. The panel will determine allocation of these funds, with no single recipient receiving more than $75,000 to allow for multiple grants to be provided.*

 

Interested researchers should complete an application (to be posted on the SMFM, ACOG and AMAG websites) and submit by June 30, 2018 to Jennifer Gudeman, AMAG Medical Affairs, at jgudeman@amagpharma.com. Research awards are expected to be announced by September 31, 2018 with funds to be provided upon execution of a research grant contract, to ensure compliance with applicable regulations.

 

2018 AMAG Research Grant application

 

*The funds from this grant program should be used exclusively for the research program and are not to be designated as general overhead.